Company intelligence / Profile preview

ViRexx Medical

Edmonton, Alberta, Canada

Ownership: Private
Employees: ~10
Development stage: Other

Overview

ViRexx Medical's lead program, OvaRex (anti-MUC1 monoclonal antibody) for ovarian cancer, failed to achieve statistical significance in Phase III trials. Chimigen Platform (HBV therapeutic vaccine) showed promising immunogenicity in preclinical and Phase I studies. Several other programs using the T-ACT and AIT platforms reached Phase I or preclinical proof-of-concept but were discontinued, outlicensed, or terminated after company acquisition.

Therapeutic areas: Women's HealthOncologyInfectious Diseases
Modalities: Monoclonal antibodyVaccineSmall moleculeBiologic
Industry: Biotech

Partnerships

United Therapeutics/Unither Pharmaceuticals (OvaRex licensing)

Beyond the preview

Go deeper on ViRexx Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViRexx Medical.

Explore the full profile